TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25197807

Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg, 20 mg, 40 mg, 80 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg, Zolpidem 10 mg, Trazodone 150 mg
Number of subjects: 353
Study: 21868715

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily on days 1 to 3 and once on day 4
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Digoxin loading dose of 0.5 mg on day 1 and 0.25 mg on days 2 to 4
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate with digoxin on days 1 to 4
Number of subjects: 23
Study: 19169664

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nutritional therapy
Number of subjects: 26
Study: 17253134

Group type: EXPERIMENTAL
Intervention: mesalazine 1.6 g/d (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mesalazine 1.6 g/d 10 days per month (group B)
Number of subjects: 40
Study: 17283930

Group type: EXPERIMENTAL
Intervention: Observers at the centre of projection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observers at other viewpoints
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of perspective cues
Number of subjects: 0
Study: 14511961

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 191

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 191
Study: 10965287

Group type: EXPERIMENTAL
Intervention: Continuation treatment (Cognitive Therapy or Phenelzine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Discontinued treatment (Pill placebo)
Number of subjects: 31
Study: 8641739

Group type: EXPERIMENTAL
Intervention: Losartan (angiotensin II receptor antagonist)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1378680

Group type: EXPERIMENTAL
Intervention: Aprotinin (2.10(6) KIU before incision, 2.10(6) KIU prior to bypass, and 5.10(5) KIU/hr for 5 hrs)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 115
Study: 6744780

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30827782

Group type: EXPERIMENTAL
Intervention: Supraflex (sirolimus-eluting stent with biodegradable polymer coating and ultra-thin struts)
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Xience (everolimus-eluting stent with durable polymer coating)
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Supraflex
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Xience
Number of subjects: 1435
Study: 29253607

Group type: EXPERIMENTAL
Intervention: Single-case experimental designs (SCED)
Number of subjects: 3
Study: 27378550

Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 23684733

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha/Theta (A/T) neurofeedback training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choreology instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 0
Study: 23022402

Group type: EXPERIMENTAL
Intervention: Coenzyme Q₁₀ (CoQ₁₀)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21041592

Group type: EXPERIMENTAL
Intervention: Culturally tailored after-school hip-hop, African, and step dance classes and a home/family-based intervention to reduce screen media use
Number of subjects: 261

Group type: COMPARATOR
Intervention: Information-based health education
Number of subjects: 261
Study: 18830043

Group type: EXPERIMENTAL
Intervention: Calcitonin (injectable form)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin (nasal spray preparations)
Number of subjects: 0
Study: 16047088

Group type: EXPERIMENTAL
Intervention: Safe Dates program
Number of subjects: 0
Study: 11809642

Group type: EXPERIMENTAL
Intervention: Fusidic acid cream
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 10084441

Group type: EXPERIMENTAL
Intervention: Low-dosage pulsed ultrasound (mean dosage 172.8 J)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-dosage pulsed ultrasound (mean dosage 345.6 J)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (sham insonation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 7597425

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Combination of doxorubicin and paclitaxel
Number of subjects: 12
Study: 1975200

Group type: EXPERIMENTAL
Intervention: mequitazine 5 mg bd
Number of subjects: 59

Group type: COMPARATOR
Intervention: terfenadine 60 mg bd
Number of subjects: 59
Study: 7443111

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17 alpha-OHP-C)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 31829925

Group type: EXPERIMENTAL
Intervention: Test formulation of atorvastatin (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of atorvastatin (20 mg)
Number of subjects: 0
Study: 29205675

Group type: EXPERIMENTAL
Intervention: Psychiatric disorder present
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 245
Study: 28551374

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention (n = 39)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional postsurgical visits (Control group, n = 35)
Number of subjects: 117
Study: 25107836

Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing laparoscopic appendectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 0
Study: 24022431

Group type: EXPERIMENTAL
Intervention: Immediate laparoscopic surgery within 24 hours of hospital admission (group ILC)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Initial antibiotic treatment followed by delayed laparoscopic cholecystectomy at days 7 to 45 (group DLC)
Number of subjects: 618
Study: 21418794

Group type: EXPERIMENTAL
Intervention: Ischemia postconditioning
Number of subjects: 64
Study: 18192924

Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan (35 patients)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-fasting during Ramadan (33 patients)
Number of subjects: 68
Study: 16891381

Group type: EXPERIMENTAL
Intervention: Irbesartan (228±93 mg/day) for at least 2 weeks prior to cardioversion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ARBs)
Number of subjects: 50
Study: 12673783

Group type: EXPERIMENTAL
Intervention: Glimepiride + NPH insulin at bedtime
Number of subjects: 261

Group type: COMPARATOR
Intervention: NPH insulin twice daily
Number of subjects: 261

Group type: COMPARATOR
Intervention: 30/70 mixture of short-acting and NPH insulin twice daily
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 261
Study: 10959995

Group type: EXPERIMENTAL
Intervention: Ultracongruent polyethylene insert
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCL-sparing design
Number of subjects: 100
Study: 9226461

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5640

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 5640
Study: 1445500

Group type: EXPERIMENTAL
Intervention: Provider referral
Number of subjects: 74

Group type: COMPARATOR
Intervention: Patient referral
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Partners notified by counselors
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Partners notified and tested
Number of subjects: 74
Study: 6141727

Group type: EXPERIMENTAL
Intervention: Nadolol alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nadolol in combination with isosorbide dinitrate and nifedipine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nadolol and large doses of nifedipine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nadolol alone and in combination with isosorbide dinitrate
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All drug combinations
Number of subjects: 19
Study: 30489496

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (40 min of uphill walking 4 d·wk at 70% heart rate reserve)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (sedentary lifestyle)
Number of subjects: 23
Study: 29894464

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 133
Study: 27054515

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 323
Study: 25536449

Group type: EXPERIMENTAL
Intervention: Management strategies including screening and treatment of subclinical hypothyroidism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 0
Study: 23731684

Group type: EXPERIMENTAL
Intervention: PEEP titrated by stress index (15.1 ± 1.8 cmH2O)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP titrated by stress index
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP titrated by stress index and oxygenation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP determined by Cst
Number of subjects: 30

Group type: COMPARATOR
Intervention: PEEP titration with the four strategies
Number of subjects: 30
Study: 20521648

Group type: EXPERIMENTAL
Intervention: Recombinant NDV expressing H9 AIV hemagglutinin (HA), administered as a single dose of 10^6 50% egg infectious dose intranasally.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Recombinant NDV expressing H9 AIV hemagglutinin (HA)
Number of subjects: 1
Study: 18447931

Group type: EXPERIMENTAL
Intervention: ECMO (Extracorporeal Membrane Oxygenation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional intensive care management
Number of subjects: 0
Study: 17064590

Group type: EXPERIMENTAL
Intervention: Prostate cancer (PCa) tissue
Number of subjects: 110
Study: 12712102

Group type: EXPERIMENTAL
Intervention: Neonates with NE with IHE
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Neonates with NE without IHE
Number of subjects: 83

Group type: COMPARATOR
Intervention: Controls (neonates without complications)
Number of subjects: 83
Study: 12964321

Group type: EXPERIMENTAL
Intervention: 12-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Number of subjects: 0
Study: 9461709

Group type: EXPERIMENTAL
Intervention: Children with advanced renal insufficiency (serum creatinine levels above 265.3 mumol/l)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Children with mild renal failure (serum creatinine levels below 265.3 mumol/l)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (27 healthy age-matched subjects)
Number of subjects: 46
Study: 7948237

Group type: EXPERIMENTAL
Intervention: Intraperitoneal vancomycin plus oral rifampin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oral trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tobramycin and ciprofloxacin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Purulent exit-site discharge
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Exit-site tenderness or swelling
Number of subjects: 126
Study: 3259681

Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 0
Study: 31488496

Group type: EXPERIMENTAL
Intervention: Australian-validated mobile health (mHealth) platform for cardiac rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28134672

Group type: EXPERIMENTAL
Intervention: Nursing students with frequent training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observers with 1-9 years experience
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observers with ≥10 years experience
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observers without any medical background
Number of subjects: 20
Study: 25092513

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioral intervention (EI)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Minimal educational intervention (MI)
Number of subjects: 296
Study: 23545360

Group type: EXPERIMENTAL
Intervention: Routine histological assessment
Number of subjects: 310

Group type: COMPARATOR
Intervention: Central review
Number of subjects: 310
Study: 21794843

Group type: EXPERIMENTAL
Intervention: Ranibizumab-treated eyes undergoing cataract surgery
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Fellow eyes of ranibizumab-treated patients undergoing cataract surgery
Number of subjects: 758

Group type: COMPARATOR
Intervention: Non-ranibizumab patients undergoing cataract surgery
Number of subjects: 758
Study: 19488999

Group type: EXPERIMENTAL
Intervention: Insulin plus 1-alpha-hydroxyvitamin D3 (1-alpha(OH)D3; 0.5 microg per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 35
Study: 16688412

Group type: EXPERIMENTAL
Intervention: Almotriptan (6.25 to 12.5 mg)
Number of subjects: 15
Study: 15305946

Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 microg/day)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: All three drugs (Triamcinolone, Montelukast, Nedocromil)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Triamcinolone vs Nedocromil
Number of subjects: 256

Group type: COMPARATOR
Intervention: Montelukast vs Nedocromil
Number of subjects: 256

Group type: COMPARATOR
Intervention: Triamcinolone vs Montelukast
Number of subjects: 256
Study: 11404533

Group type: EXPERIMENTAL
Intervention: Nevirapine combined with nelfinavir and two NRTIs
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 9199951

Group type: EXPERIMENTAL
Intervention: Quantitative Coronary Angiography (QCA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 3-D Intracoronary Ultrasound (ICUS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: QCA
Number of subjects: 49
Study: 8217174

Group type: EXPERIMENTAL
Intervention: 5% dextrose and lactated Ringer's solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal saline infusions
Number of subjects: 33
Study: 31368121

Group type: EXPERIMENTAL
Intervention: Single implant mandibular overdenture (SIO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 22
Study: 30567497

Group type: EXPERIMENTAL
Intervention: Checklist intervention for antihypertensive medication initiation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard care without checklist (control group)
Number of subjects: 119
Study: 26851734

Group type: EXPERIMENTAL
Intervention: Opt-out condition (N=61): Participants received an e-mail with a pre-scheduled appointment for influenza vaccination.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Opt-in condition (N=61): Participants received an e-mail explaining that they had to schedule an appointment if they wanted to get vaccinated.
Number of subjects: 122
Study: 24827469

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice weekly for 6 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (acupuncture started 6 weeks after enrollment)
Number of subjects: 100
Study: 23055497

Group type: EXPERIMENTAL
Intervention: Wavering wolf display (wolf chasing with changing intentions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wolf chasing with a single unchanging intention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similar patterns of motion that are not perceived as goal-directed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abrupt onsets and offsets of moving objects
Number of subjects: 0
Study: 21198566

Group type: EXPERIMENTAL
Intervention: TMS with PM
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TMS without PM
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sham with PM
Number of subjects: 164
Study: 17931620

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: therapeutic lifestyle changes intervention
Number of subjects: 80
Study: 16003267

Group type: EXPERIMENTAL
Intervention: Preload reduction with Valsalva maneuver (nonstandardized and standardized) and sublingual nitroglycerin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulmonary venous Doppler
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standardized Valsalva or pharmacologic preload reduction
Number of subjects: 45
Study: 12033698

Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF) therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET)
Number of subjects: 205
Study: 10204758

Group type: EXPERIMENTAL
Intervention: Self-efficacy measures (Arthritis Self Efficacy Scale - ASES)
Number of subjects: 128
Study: 7564453

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 gm intravenously over 20 minutes before sternotomy and a placebo infusion over 5 hours)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 gm intravenously over 20 minutes and another 10 gm infused over 5 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline solution bolus and infusion over 5 hours)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 gm)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continued tranexamic acid infusion (10 gm over 5 hours)
Number of subjects: 150
Study: 2075481

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg (regimen A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg (regimen B)
Number of subjects: 34
Study: 6992823

Group type: EXPERIMENTAL
Intervention: Labetalol (400-800 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Labetalol (1200-1600 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acebutolol (400-800 mg daily)
Number of subjects: 40
Study: 30549273

Group type: EXPERIMENTAL
Intervention: hrHPV testing every 5 years
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Cytology testing every 3 years
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Five different combinations of abnormal screening test results
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Long-term anxiety or depression scores (4-24 months after screening)
Number of subjects: 1008
Study: 30527615

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1366
Study: 27662018

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (4 cycles of standard anthracycline-based chemotherapy)
Number of subjects: 434

Group type: COMPARATOR
Intervention: No induction chemotherapy
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (per protocol)
Number of subjects: 434

Group type: COMPARATOR
Intervention: No induction chemotherapy (per protocol)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: MEL140 (high-dose melphalan)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Mobilization chemotherapy and tandem MEL140
Number of subjects: 434
Study: 24568260

Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TrPDN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No intervention (waiting list)
Number of subjects: 17
Study: 22248762

Group type: EXPERIMENTAL
Intervention: 10 mL to 0.5% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mL to 0.5% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mL to 1% ropivacaine
Number of subjects: 60
Study: 20389068

Group type: EXPERIMENTAL
Intervention: Visual TTP-DWI mismatch assessment by experienced rater
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Visual TTP-DWI mismatch assessment by inexperienced raters
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Visual T(max)-DWI mismatch assessment by experienced rater
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Visual T(max)-DWI mismatch assessment by inexperienced raters
Number of subjects: 99

Group type: COMPARATOR
Intervention: Volumetric calculation of perfusion-diffusion mismatch
Number of subjects: 99
Study: 17118993

Group type: EXPERIMENTAL
Intervention: Exercise (45 min at 95% of lactate threshold)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Counterregulatory hormones during exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 9
Study: 16301144

Group type: EXPERIMENTAL
Intervention: Biodegradable osteosynthesis materials
Number of subjects: 54

Group type: COMPARATOR
Intervention: Titanium fixation system (rescue osteosynthesis)
Number of subjects: 54
Study: 11916896

Group type: EXPERIMENTAL
Intervention: Comprehensive, moderate intensity, group exercise
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Daily micronutrient enriched foods (25‐100% recommended daily amount)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both exercise and micronutrient supplementation
Number of subjects: 139

Group type: COMPARATOR
Intervention: Neither intervention (attention control and placebo)
Number of subjects: 139